{"id":"amb-05x","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL414723","moleculeType":"Small molecule","molecularWeight":"1669.88"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AMB-05X works by selectively inhibiting the PI3K delta subunit, which is involved in the activation of immune cells. This inhibition leads to a reduction in the activity of these cells, resulting in a decrease in inflammation and potentially reducing the severity of autoimmune diseases.","oneSentence":"AMB-05X is a small molecule inhibitor of the PI3K delta subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:46.284Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT06617858","phase":"PHASE2","title":"Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-12-04","conditions":"Colorectal Cancer","enrollment":15},{"nctId":"NCT05349643","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT","status":"COMPLETED","sponsor":"AmMax Bio, Inc.","startDate":"2023-01-26","conditions":"Pigmented Villonodular Synovitis, TGCT, Tenosynovial Giant Cell Tumor","enrollment":20},{"nctId":"NCT04731675","phase":"PHASE2","title":"An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee","status":"COMPLETED","sponsor":"AmMax Bio, Inc.","startDate":"2021-05-25","conditions":"Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis (PVNS)","enrollment":11},{"nctId":"NCT04938180","phase":"PHASE2","title":"A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients","status":"TERMINATED","sponsor":"AmMax Bio, Inc.","startDate":"2021-09-16","conditions":"Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, TGCT","enrollment":4},{"nctId":"NCT05349760","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Safety and Efficacy of AMB-05X in Subjects With Idiopathic Pulmonary Fibrosis","status":"WITHDRAWN","sponsor":"AmMax Bio, Inc.","startDate":"2023-03","conditions":"IPF","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AMB-05X","genericName":"AMB-05X","companyName":"AmMax Bio, Inc.","companyId":"ammax-bio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AMB-05X is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}